Across 257 European CTIS Phase III immunology trials authorised from 2024–2026, CRO or CRO-like operational support appears in 162 trials, or 63.0%. IQVIA is the most active named provider with 66/257 trials, followed by ICON with 56/257, PPD / Thermo Fisher with 42/257, and Parexel with 39/257. CRO need is most visible when trials reach large EU operating scale: 54/57 trials with 11+ countries, 36/41 trials with 51+ sites, and 9/11 trials with 801+ planned participants used CRO support.
The most active named support organisations are IQVIA in 66/257 trials (25.7%), ICON in 56/257 (21.8%), PPD / Thermo Fisher in 42/257 (16.3%), and Parexel in 39/257 (15.2%). The ranking includes organisations flagged in sponsor records as CRO or operational trial support parties.
The top of the market is concentrated around global CROs and large trial-platform vendors. IQVIA and ICON appear most often, but the frequent appearance of Medidata, Clario/Calyx/ERT, Suvoda, Signant, YPrime and 4G Clinical shows that Phase III immunology outsourcing is not only full-service execution; it is also technology, data capture, randomisation, patient-reported outcomes and country-level operations.
Only 8/67 single-country trials used CRO support (11.9%), compared with 43/68 trials across 2–5 countries (63.2%), 57/65 trials across 6–10 countries (87.7%), and 54/57 trials across 11+ countries (94.7%). Site footprint shows the same pattern: CRO support appears in 36/41 trials with 51+ sites (87.8%).
| Capacity tier | CRO trials | Share |
|---|---|---|
| 1 country | 8/67 | 11.9% |
| 2–5 countries | 43/68 | 63.2% |
| 6–10 countries | 57/65 | 87.7% |
| 11+ countries | 54/57 | 94.7% |
| 51+ sites | 36/41 | 87.8% |
| 801+ planned participants | 9/11 | 81.8% |
The strongest operational trigger is EU scale, not only participant volume. Trials crossing 6 countries already show 87.7% CRO use, and those crossing 11 countries reach 94.7%, indicating that CTIS Part II coordination, country submissions, site activation and vendor oversight are where external support becomes most structurally necessary.
The indications with the most CRO-supported trials are psoriatic arthritis and systemic lupus erythematosus, each with 8 CRO-supported trials. Crohn's disease is smaller but fully outsourced in this cohort, with 6/6 trials using CRO support (100.0%). Generalized myasthenia gravis and hereditary angioedema also show 5/5 CRO-supported trials each (100.0%).
CRO demand is strongest where Phase III immunology studies combine broad European rollout with complex patient identification or specialist site networks. Psoriatic arthritis, lupus and Crohn's disease create scale demand, while hereditary angioedema, generalized myasthenia gravis and IgA nephropathy create specialised-site and rare-disease coordination demand.
The most frequently outsourced function category is trial technology, data capture and randomisation, appearing in 100/257 trials (38.9%) and 100/162 CRO-supported trials (61.7%). Broad CTIS sponsor-duty codes or multi-duty CRO operations appear in 84/257 trials (32.7%), while laboratory, bioanalytical and sample-management support appears in 70/257 trials (27.2%).
The core outsourced need is operational infrastructure rather than only clinical monitoring. eCOA/ePRO, IRT/IVRS, EDC, randomisation, central labs, sample logistics, site payments and CTIS sponsor-duty execution are the main externalised work packages in European Phase III immunology trials.
Across 257 trials, the median time from initial CTIS submission to first CTIS authorisation is 105 days. CRO-supported trials show a higher median of 111 days across 162 trials, compared with 90 days across 95 non-CRO trials. Country-level CTIS Part II processing has a median of 96 days across 1,204 country submissions.
CRO-supported trials have longer CTIS submission-to-authorisation medians because they are also more multinational and operationally complex. For CRO business development, CTIS Part II country coordination is a practical trigger: the largest recurring countries are Spain, Germany, France, Italy and Poland, all appearing in roughly half or more of the cohort.
Among drug modalities, CRO support is most frequent for other antibody trials at 9/10 (90.0%), monoclonal antibody trials at 83/114 (72.8%), peptide/protein/enzyme trials at 28/41 (68.3%), and small molecule trials at 67/103 (65.0%). Recruitment model is an even stronger signal: 74/77 digital or remote recruitment trials (96.1%) and 28/30 registry or advocacy recruitment trials (93.3%) used CRO support.
| Signal | CRO-supported | Rate |
|---|---|---|
| Digital or remote recruitment | 74/77 | 96.1% |
| Registry or advocacy recruitment | 28/30 | 93.3% |
| Orphan-drug trials | 38/42 | 90.5% |
| Biomarker-stratified trials | 6/7 | 85.7% |
| Paediatric trials | 62/81 | 76.5% |
| Monoclonal antibody trials | 83/114 | 72.8% |
The clearest adjacent CRO-demand questions are not just “which disease?” but “which operating model?” Digital recruitment, advocacy outreach, orphan status, paediatric consent and biologic/antibody development all raise the need for specialist vendors, country-specific materials, patient-facing logistics and tighter EU submission coordination.
Pharmaceutical-company sponsors account for 205/257 trials (79.8%) and 159/205 of those pharma-sponsored trials use CRO support (77.6%). Hospital or clinic sponsors account for 41/257 trials (16.0%) and 0/41 use CRO support in the extracted CRO field.
The commercial CRO opportunity is concentrated in pharma-led Phase III immunology. Hospital-led studies may still need services, but they are not commonly captured as CRO-supported in the CTIS sponsor-party field; pharma sponsors are the clearest high-probability buyer segment for CTIS submission support, multi-country site activation and vendor-managed trial infrastructure.
The European Phase III immunology CRO market is capacity-triggered. CRO support is present in 162/257 trials overall, but it becomes near-standard at 11+ countries (54/57; 94.7%), 51+ sites (36/41; 87.8%), orphan-drug trials (38/42; 90.5%), and trials using digital or remote recruitment (74/77; 96.1%). The strongest service demand is for CTIS/EU submission coordination, trial technology, lab and sample logistics, site operations, recruitment materials, patient logistics and country-level execution.